Should You Sell to a Corporate Dental Buyer or Stay Independent?

The question comes up in almost every exit conversation we have with practice owners. You have built a dental practice over years, perhaps decades. Now a corporate acquirer approaches you, or you start thinking about an independent sale to an associate or a smaller group. Which route gives you better value, less tax, and a cleaner exit?

The short answer is that it depends on your practice's mix of NHS and private work, your personal tax position, and how much control you want after the sale. This article compares the two paths using real figures and the 2025/26 tax rules. We focus on the financial and practical differences, not the marketing gloss.

What Counts as a Corporate Dental Buyer?

In the UK dental market, the main corporate acquirers are Bupa Dental Care, MyDentist, Portman Dental Care, and a handful of other groups such as Oasis (now part of Bupa), Rodericks, and smaller regional consolidators. These groups typically buy practices outright, retain the existing team, and integrate the practice into their centralised support structure.

Corporate buyers usually pay a higher headline price for a practice than an independent buyer would. They have access to cheaper debt finance, economies of scale in procurement and back-office functions, and a clear strategy to roll up practices into a larger network. The trade-off is that you lose operational control, and the sale process can be slower and more bureaucratic.

Independent Sale: What Does That Mean?

An independent sale means selling to another dentist, a small partnership, or a local group that does not belong to a national corporate chain. The buyer might be an associate who wants to become a principal, a dentist from another region looking to relocate, or a small group of two or three practices.

Independent buyers typically pay less than corporates on a headline basis. They cannot access the same cheap debt, and they lack the centralised cost savings that corporates use to justify higher multiples. However, independent sales often complete faster, involve less due diligence, and give you more flexibility on terms such as a phased handover or a retained role.

Valuation Differences: Corporate vs Independent

Practice valuation methods are the same regardless of buyer type: you value the tangible assets (equipment, goodwill, property if owned) and apply a multiple to maintainable earnings. But the multiple varies significantly.

For a typical mixed NHS-private practice with 60% NHS and 40% private income, a corporate buyer might offer a goodwill multiple of 0.8 to 1.2 times adjusted EBITDA. An independent buyer might offer 0.5 to 0.8 times. The gap narrows for high-private practices: a 90% private practice could attract 1.0 to 1.4 times from a corporate and 0.7 to 1.0 times from an independent buyer.

Worked example: A practice with adjusted EBITDA of £300,000. Corporate offer at 1.0x EBITDA = £300,000 goodwill value. Independent offer at 0.7x = £210,000. The corporate pays £90,000 more for goodwill alone. But that headline gap does not tell the whole story, as we will see.

Tax Treatment of the Sale

Both sale routes are capital disposals, not trading income. Gains are subject to Capital Gains Tax (CGT), not income tax. The key relief is Business Asset Disposal Relief (BADR), which in 2025/26 gives a 14% tax rate on the first £1 million of lifetime gains, rising to 18% from 6 April 2026.

If you sell to a corporate buyer, you typically receive cash. If you sell to an independent buyer, you might receive a mix of cash and deferred consideration, or shares in the buyer's company if they are a limited company. Deferred consideration can create a tax complication: if the earn-out is contingent on future performance, HMRC may treat part of it as income rather than capital. This is less common with corporate buyers, who usually pay all cash on completion.

Worked example: Sale to corporate for £300,000 cash. BADR applies to the first £1m of gains. Assuming the entire gain is within the BADR limit, tax at 14% = £42,000. Net proceeds = £258,000. Sale to independent for £210,000 cash plus £40,000 earn-out over two years based on UDA delivery. The earn-out may be taxed as income at 40% or 45%, reducing net proceeds further. The headline gap narrows.

Timeline and Process Differences

Corporate buyers have dedicated acquisitions teams. They run a standardised due diligence process that covers financials, contracts, premises, equipment, staff, and compliance. The process typically takes 4 to 8 months from initial approach to completion. Delays are common if the practice has incomplete records, unresolved NHS contract issues, or property lease problems.

Independent buyers are usually less formal. A sale to an associate who knows the practice already can complete in 2 to 4 months. The due diligence is lighter, often limited to a review of accounts, the NHS contract, and the property lease. The risk is that the independent buyer may struggle to secure finance, especially if they are a first-time buyer with limited capital.

Post-Sale Role and Restrictions

Corporate buyers typically want the selling principal to stay on for 6 to 12 months as a salaried associate or clinical director. This ensures continuity for patients and staff. After that, you are free to leave, but non-compete clauses are common: typically 2 to 5 years within a defined radius (often 5 to 10 miles).

Independent buyers are more flexible. You might agree to work part-time for a few years, or retire immediately. Non-compete clauses are usually shorter and narrower, reflecting the smaller scale of the buyer's operations. Some independent buyers are happy for you to continue working in the same practice as an associate without restriction.

NHS Contract Considerations

The NHS contract (General Dental Services or Personal Dental Services agreement) is a key asset. Corporate buyers value contracts with stable UDA delivery and good performance history. They are less interested in contracts with high UDA values but poor delivery records, because they have the systems to improve performance.

Independent buyers may be more concerned about the contract's transferability. NHS England (or the equivalent body in Wales, Scotland, or Northern Ireland) must approve the change of contractor. This approval is not guaranteed. If the contract is at risk of being terminated or re-tendered, a corporate buyer may walk away, while an independent buyer with local relationships might negotiate a better outcome.

For more detail on how NHS contracts affect practice value, see our NHS contract essentials guide for dentists.

Property: Owned or Leased?

If you own the practice premises, you have a second asset to sell. Corporate buyers often prefer to buy the property as well, paying a separate price based on market value. This can increase your total proceeds significantly. However, if the property is held in a separate company or personally, the tax treatment differs: property gains may qualify for BADR if the property is used in the trade, but HMRC often challenges this.

Independent buyers are more likely to lease the property from you, generating ongoing rental income. This can be tax-efficient if you have no other use for the capital, but it creates a continuing connection to the practice that may not suit a clean exit.

Which Route Suits Different Practice Types?

High-private practices (80%+ private income): Corporate buyers pay a premium for these because private income is more predictable and less regulated. The valuation gap between corporate and independent is widest here. If you want maximum cash, sell to a corporate.

NHS-heavy practices (70%+ NHS): Corporate buyers are still interested, but the multiple is lower. Independent buyers may offer a similar multiple if they have a strong local reputation and can maintain UDA delivery. The gap is narrower.

Small single-handed practices (under £200k turnover): Corporate buyers often pass on these because the acquisition cost is too high relative to the return. Independent sale to an associate or a local dentist is the realistic path.

Multi-site groups: Corporate buyers are the natural exit route. Independent buyers rarely have the capital or management bandwidth to acquire multiple sites in one transaction.

Practical Steps Before You Decide

Before approaching any buyer, get a professional valuation. Our practice valuation service uses EBITDA multiples and market comparables specific to your region and practice mix. Do not rely on a buyer's initial offer as your benchmark.

Review your NHS contract. Check the UDA value, the annual target, and the clawback risk. A contract with a history of clawback is less attractive to any buyer. Our NHS UDA value calculator can help you understand your contract's financial profile.

Consider your personal tax position. If you have other capital gains in the same tax year, or if your gains exceed the BADR lifetime limit, the effective tax rate changes. Speak to a dental-specialist accountant before signing anything.

Think about your post-sale life. Do you want to work part-time? Retire completely? Start another practice? Corporate buyers offer a structured exit with a defined end date. Independent buyers offer more flexibility but less certainty.

Summary: Corporate vs Independent

FactorCorporate BuyerIndependent Buyer
Headline priceHigher (0.8-1.4x EBITDA)Lower (0.5-1.0x EBITDA)
Tax treatmentCash, BADR-eligibleMay include earn-out, income tax risk
Timeline4-8 months2-4 months
Due diligenceExtensiveLight
Post-sale role6-12 months salariedFlexible
Non-compete2-5 years, wide radiusShorter, narrower
PropertyOften boughtOften leased

The right path depends on your priorities. If maximum cash and a clean break matter most, a corporate sale is usually better. If you value flexibility, a shorter process, and a continuing connection to the practice, an independent sale may suit you better. Either way, get professional advice early.

For a full assessment of your practice's sale options, including tax modelling and buyer comparison, see our dental accountancy services or book a free practice health check.